Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib and avelumab in epithelial ovarian cancer
NCT02943317Phase 1Terminated
- Sponsor
- Verastem Oncology
- Start
- Oct 2016
- Primary completion
- Aug 2018
- Countries
- 1
01
Overview
Phase 1, open-label trial of defactinib in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Verastem Oncology. Primary endpoints: Adverse Events at 90 days, Maximum Tolerated Dose at 28 days and 1 more. Started Oct 2016; status: terminated.
02
Drugs
defactinib
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02943317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02943317.